FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889553363> ?p ?o ?g. }

• W2889553363 endingPage "698" @default.
• W2889553363 startingPage "684" @default.
• W2889553363 abstract "Lysyl oxidase like‐2 (LOXL2) plays a central role in fibrogenesis and is elevated in the serum and liver of patients with primary sclerosing cholangitis (PSC). We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody directed against LOXL2, in patients with PSC. Patients with compensated liver disease caused by PSC were randomized 1:1:1 to receive weekly subcutaneous injections of simtuzumab 75 mg, simtuzumab 125 mg, or placebo for 96 weeks. The primary efficacy endpoint was mean change in hepatic collagen content assessed by morphometry between baseline and week 96. Additional endpoints included change in Ishak fibrosis stage and the frequency of PSC‐related clinical events. Overall, 234 patients were randomized and started treatment. At week 96, the mean change from baseline in hepatic collagen content was –0.5% for patients receiving simtuzumab 75 mg (P = 0.73 versus placebo), +0.5% for patients receiving simtuzumab 125 mg (P = 0.33 versus placebo), and 0.0 for patients receiving placebo. Compared with placebo, neither dose of simtuzumab led to significant reductions in Ishak fibrosis stage, progression to cirrhosis, or frequency of clinical events. Overall, 80 (34%) patients had fibrosis progression and 47 (20%) experienced PSC‐related clinical events. In a multivariate model of baseline factors, PSC‐related clinical events were more frequent in patients with advanced fibrosis (hazard ratio [HR], 2.03; 95% confidence interval [CI], 1.02‐4.06; P = 0.045), higher alkaline phosphatase (HR per 10 U/L, 1.01; 95% CI, 1.00‐1.02; P = 0.015), and higher enhanced liver fibrosis score (HR per unit, 1.26; 95% CI, 0.98‐1.61; P = 0.073). Overall, rates of adverse events and laboratory abnormalities were similar between groups. Conclusion: Treatment with the LOXL2 inhibitor simtuzumab for 96 weeks did not provide clinical benefit in patients with PSC." @default.
• W2889553363 created "2018-09-07" @default.
• W2889553363 creator A5002183557 @default.
• W2889553363 creator A5010123528 @default.
• W2889553363 creator A5010968373 @default.
• W2889553363 creator A5013219986 @default.
• W2889553363 creator A5018022782 @default.
• W2889553363 creator A5024470010 @default.
• W2889553363 creator A5027014361 @default.
• W2889553363 creator A5027753564 @default.
• W2889553363 creator A5028673328 @default.
• W2889553363 creator A5029813521 @default.
• W2889553363 creator A5035673731 @default.
• W2889553363 creator A5038426997 @default.
• W2889553363 creator A5043626370 @default.
• W2889553363 creator A5045437302 @default.
• W2889553363 creator A5055168302 @default.
• W2889553363 creator A5055800275 @default.
• W2889553363 creator A5060508119 @default.
• W2889553363 creator A5064179616 @default.
• W2889553363 creator A5088683463 @default.
• W2889553363 creator A5088845309 @default.
• W2889553363 date "2019-01-11" @default.
• W2889553363 modified "2023-10-18" @default.
• W2889553363 title "Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease" @default.
• W2889553363 cites W1479884833 @default.
• W2889553363 cites W1559553970 @default.
• W2889553363 cites W1986107053 @default.
• W2889553363 cites W2001090095 @default.
• W2889553363 cites W2005901103 @default.
• W2889553363 cites W2005913737 @default.
• W2889553363 cites W2019796203 @default.
• W2889553363 cites W2023000637 @default.
• W2889553363 cites W2058589857 @default.
• W2889553363 cites W2065282846 @default.
• W2889553363 cites W2080820626 @default.
• W2889553363 cites W2097059887 @default.
• W2889553363 cites W2102005215 @default.
• W2889553363 cites W2118181901 @default.
• W2889553363 cites W2125763073 @default.
• W2889553363 cites W2133403920 @default.
• W2889553363 cites W2140206473 @default.
• W2889553363 cites W2146286872 @default.
• W2889553363 cites W2408729117 @default.
• W2889553363 cites W2560640434 @default.
• W2889553363 cites W2570320388 @default.
• W2889553363 cites W2572106801 @default.
• W2889553363 cites W2590741349 @default.
• W2889553363 cites W2592181184 @default.
• W2889553363 cites W2593027881 @default.
• W2889553363 cites W2594589478 @default.
• W2889553363 cites W2745107259 @default.
• W2889553363 cites W2770523913 @default.
• W2889553363 cites W2781877987 @default.
• W2889553363 cites W2821544409 @default.
• W2889553363 cites W3144026819 @default.
• W2889553363 doi "https://doi.org/10.1002/hep.30237" @default.
• W2889553363 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30153359" @default.
• W2889553363 hasPublicationYear "2019" @default.
• W2889553363 type Work @default.
• W2889553363 sameAs 2889553363 @default.
• W2889553363 citedByCount "110" @default.
• W2889553363 countsByYear W28895533632018 @default.
• W2889553363 countsByYear W28895533632019 @default.
• W2889553363 countsByYear W28895533632020 @default.
• W2889553363 countsByYear W28895533632021 @default.
• W2889553363 countsByYear W28895533632022 @default.
• W2889553363 countsByYear W28895533632023 @default.
• W2889553363 crossrefType "journal-article" @default.
• W2889553363 hasAuthorship W2889553363A5002183557 @default.
• W2889553363 hasAuthorship W2889553363A5010123528 @default.
• W2889553363 hasAuthorship W2889553363A5010968373 @default.
• W2889553363 hasAuthorship W2889553363A5013219986 @default.
• W2889553363 hasAuthorship W2889553363A5018022782 @default.
• W2889553363 hasAuthorship W2889553363A5024470010 @default.
• W2889553363 hasAuthorship W2889553363A5027014361 @default.
• W2889553363 hasAuthorship W2889553363A5027753564 @default.
• W2889553363 hasAuthorship W2889553363A5028673328 @default.
• W2889553363 hasAuthorship W2889553363A5029813521 @default.
• W2889553363 hasAuthorship W2889553363A5035673731 @default.
• W2889553363 hasAuthorship W2889553363A5038426997 @default.
• W2889553363 hasAuthorship W2889553363A5043626370 @default.
• W2889553363 hasAuthorship W2889553363A5045437302 @default.
• W2889553363 hasAuthorship W2889553363A5055168302 @default.
• W2889553363 hasAuthorship W2889553363A5055800275 @default.
• W2889553363 hasAuthorship W2889553363A5060508119 @default.
• W2889553363 hasAuthorship W2889553363A5064179616 @default.
• W2889553363 hasAuthorship W2889553363A5088683463 @default.
• W2889553363 hasAuthorship W2889553363A5088845309 @default.
• W2889553363 hasConcept C126322002 @default.
• W2889553363 hasConcept C142724271 @default.
• W2889553363 hasConcept C168563851 @default.
• W2889553363 hasConcept C197934379 @default.
• W2889553363 hasConcept C203092338 @default.
• W2889553363 hasConcept C204787440 @default.
• W2889553363 hasConcept C207103383 @default.
• W2889553363 hasConcept C27081682 @default.
• W2889553363 hasConcept C2777214474 @default.

• next